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http://www.ped-rheum.com/content/12/1/2RESEARCH Open AccessJuvenile dermatomyositis in South African
children is characterised by frequent dystropic
calcification: a cross sectional study
Gail Faller1*, Bhadrish J Mistry1 and Mohammed Tikly2Abstract
Background: To describe Juvenile dermatomyositis (JDM) that has rarely been reported in Sub-Saharan Africa in
children.
Methods: Retrospective record review of children with JDM attending a tertiary hospital in South Africa.
Results: Twenty-one children (16 female, five male) with JDM had a mean (SD) age at presentation of 9.8 (3.3)
years. Mean follow-up period was 2.6 (2.2) years. The commonest presenting features were skin rash (71%), muscle
weakness (71%), inflammatory arthritis (42%) and calcinosis (29%). The cumulative frequency of calcinosis was 71%.
Skin vasculitis was present in 9(43%), and 7 (33%) had Staphylococcus aureus infections. Calcinosis was strongly
associated with vasculitis; 11/15 (73.3%) with calcinosis had vasculitis versus 0/6 without vasculitis (p = 0.003).
Patients with calcinosis had significantly lower creatinine kinase (CK) levels compared to those without calcinosis
[mean (SD) 272 U/L (401) vs. 2414 U/L (3201), respectively, p = 0.016]. All children with calcinosis had Staphylococcus
aureus infection, but there was no significant difference in their duration of symptoms to presentation. Joint
contractures, occurring in eight patients (38%), were associated with a significantly lower age at presentation [mean
(SD) 6.8(2.8) vs. 11.6(2.1) years (no contractures) p = 0.0003], and significantly higher CRP and ESR levels. Three
patients were lost to follow-up, two died. In the remaining 16 patients: 10 (47%) experienced remission, 2 relapsed
and 4 persistent active disease.
Conclusion: African children with JDM have increased vasculitic disease and high levels of calcinosis with low
muscle enzymes, particularly CK. Younger children are at higher risk of contractures and disability. Patients are at
high risk of developing Staphylococcus aureus infection. Rapid and aggressive therapy is necessary.
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Juvenile dermatomyositis (JDM) is a systemic capillary
vasculopathy affecting primarily the skin and muscles
and less frequently the gastrointestinal tract, myocar-
dium and lungs. Clinical presentation varies from a cata-
strophic presentation of severe weakness (or paralysis),
swallowing abnormalities and myocarditis, to a more in-
sidious onset of muscle weakness [1]. Diagnosis is still
largely based on diagnostic criteria of Bohan and Peter
[2,3], but more recently MRI features suggestive an* Correspondence: gail.faller@iburst.co.za
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stated.inflammatory myositis have been used [4] and an inter-
national consensus study network for juvenile dermato-
myositis has proposed other useful criteria including
calcinosis, dysphonia, nailfold capillary changes and
myopathic changes on EMG [5].
Juvenile dermatomyositis is rare with an incidence of 1.9-
4.1 per million in industrialised countries. It has a female
preponderance across all age groups [6,7]. While regional
differences are known to play a role, it is unknown whether
it is more common in people of African extraction [8]. In
recent years, mortality due to JDM has declined consider-
ably but morbidity related to the myopathy, calcinosis and
long-term use of corticosteroids remains a major challenge
[9].td. This is an Open Access article distributed under the terms of the Creative
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Table 1 Demographic and clinical features of South
African children with dermatomyositis





Mean (SD) age in years 9.8.(3.3)




Proximal weakness 10/21(48) 10/21(48)








Interstitial lung disease 1/21(5) 2/21(10)
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http://www.ped-rheum.com/content/12/1/2To date there have been no published reports of JDM
in Sub-Saharan Africans. We therefore undertook a
retrospective study of the clinical presentation and out-
come of JDM in South African children attending a ter-
tiary hospital. The study was approved by Human Ethics
Committee of the Faculty of Health Sciences, University
of the Witwatersrand, Johannesburg, South Africa.
Methods
A retrospective record review was conducted of children
and adolescents who fulfilled the Bohan and Peter criteria
[2,3] for JDM and were diagnosed between January 1998
and December 2009. The patients were attending the
paediatric and adult rheumatology clinics at the Chris Hani
Academic Baragwanath Academic Hospital, Johannesburg,
South Africa. This is a tertiary care center serving the pre-
dominantly Black population of Soweto and surrounding
areas. The paediatric rheumatology clinic is the larger of
only 2 paediatric rheumatology clinics in the northern part
of South Africa, and most patients with rheumatological
conditions from district hospitals, primary care facilities
and paediatricians are referred to this clinic. Data ab-
stracted from case notes included demographics, clinical
and laboratory features at diagnosis, medical treatment and
outcome. As data concerning muscle biopsies was not al-
ways available, this was not included, and routine capillaro-
scopy was not performed. The subtypes of calcinosis were
defined according to the classification by Blane et al. [10].
Global weakness was defined as weakness that extended be-
yond the usual muscles identified as most often affected in
JDM (that is, the hip flexors, hip extensors, hip abductors,
neck flexors and shoulder abductors) and therefore in-
cluded peripheral weakness (hands and feet) and abdominal
muscles [11]. Weakness was assessed by standard manual
muscle testing.
Statistical methods
The Students t-test was applied to compare continuous
variables and the two-tailed Fisher’s exact test in the case
of categorical variables. All statistical analyses were done
using the Statistica v10 software [12]. A p value <0.05
was considered to be significant.
Results
All the patients were Black Africans and, as shown in
Table 1, more than 75% of the 21 patients were female. The
mean age at presentation was just under 10 years with a
mean follow-up period of 31.6 months. At presentation, the
commonest features were skin rashes (Gottron’s papules,
heliotrope or malar rash or a combination thereof) in 90%,
and proximal muscle weakness and arthritis each in 48% of
patients. Although 10% of children were not described to
have typical rashes at presentation, these were identified
during the follow-up course.As shown in Table 2, patients with global weakness were
younger (p = 0.04), had higher baseline acute phase re-
sponses, CRP (p = 0.03) and ESR (p = 0.007). Joint Contrac-
tures (defined as limited range of movement,) occurred in 8
patients, were associated with a younger age of disease on-
set (p = 0.003) and higher baseline acute phase responses:
CRP (p = 0.01) and ESR (p = 0.04). Two of the 5 patients
with global weakness had associated dysphagia necessitat-
ing naso-gastric tube feeding, 1 of whom was also in con-
gestive cardiac failure.
A third of the patients had calcinosis at presentation
and a further 38% developed this complication during
the follow-up period. The subtypes of calcinosis were
superficial nodules in 4 (26.6%), deep muscle tumoural
calcification in 5, (33.3%), and mixed calcification types
in the remaining 6 (40%) including along fascial planes
and exoskeleton formation. The mean duration of symp-
toms of disease prior to presentation in patients with
calcinosis (as described by their care-givers) was 9.2,
(9.4) months compared to those who did not develop
calcinosis at 4.5 [3] months. This difference was not sta-
tistically significant (p = 0.24).
The presence of skin vasculitis, as defined by the pres-
ence of vasculopathic lesions with cutaneous ulceration,
had the strongest association with calcinosis (p = 0.003)
(Table 2). The muscle enzymes, CK and aldolase, were
significantly lower in patients with calcinosis (p = 0.02
and 0.003, respectively).
Vasculitis and Staphylococcus aureus infection oc-
curred exclusively in patients with calcinosis.
Staphylococcus aureus infection occurred in one third
of patients, all of whom had calcinosis; in 4 the infection
presented as abscess formation in association with the
Table 2 Clinico-laboratory correlates
Global weakness Present (n = 5) Absent (n = 16) p value
Age - mean (SD) years 7.3(2) 10.5(3.3) 0.04
CRP - mean (SD) mg/l 52(81) 4(4.5) 0.03
ESR - mean (SD) mm/hr 83(41) 24(25) 0.007
Contractures Present (n = 8) Absent (n = 13)
Age - mean (SD) years 6.8(3) 11.6(2) 0.0003
CRP - mean (SD) mg/l 45(75) 3.8(3.9) 0.000
ESR - mean (SD) mm/hr 59(48) 25(26) 0.04
Calcinosis Present (n = 15) Absent (n = 6)
Age-mean (SD) years 9.1(3.5) 11.3(2) 0.18
Duration of follow-up - mean (SD) (months) 39 (28) 13(14) 0.04
CK - mean (SD) IU/l 288 (402) 2414(3201) 0.02
Aldolase mean (SD) IU/ 18.5 (12.6) 38.6(23.5) 0.03
Vasculitis (%) 11(73.3) 0 (0) 0.003
Staphylococcus aureus infection (%) 7 (46,7) 0 (0) 0.04
Staphylococcus aureus infection Present (n = 7) Absent (n = 14)
Duration of follow-up - mean (SD) (months) 51(32) 22(20) 0.02
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litis) and 1 had septicaemia. In all these patient positive
cultures were obtained from pus swabs or blood cul-
tures. The patients who developed Staphylococcus aur-
eus infection had a significantly longer follow-up period
(p = 0.01).
Interstitial lung disease occurred in 2 (12%), both of
whom developed cor pulmonale. Two patients contracted
tuberculosis (TB), 1 pulmonary and the other TB arthritis.
The diagnosis in both cases was confirmed by Mycobacter-
ium Tuberculosis culture. One child had uveitis at presen-
tation and another developed it during the disease course.
Laboratory features
Only five patients were antinuclear antibody (ANA)
positive and all except one had elevation of at least one
muscle enzyme, with aldolase abnormal in 18/21 (85%)
and creatinine kinase (CK) in 10/21 (48%). Lactate de-
hydrogenase (LDH) was not done routinely but was
raised in 7 of 9 children tested (33%). There was lym-
phopenia (total count less than 1.5 × 109) in six patients
(29%). Baseline erythrocyte sedimentation rate (ESR)
was high in eight patients (38%) and CRP in six (28%).
Medical treatment
The myositis was treated from presentation with oral corti-
costeroids with the exception of 3 patients. These 3 were
initially treated with intravenous methylprednisolone
(30 mg/kg to a maximum of 1 g) followed by oral cortico-
steroid; 2 of these children had calcinosis at presentation.
Oral corticosteroid was given in a dose of 2 mg/kg (max-
imum 60 mg) as a daily dose and weaned according toindividual response. No patient’s corticosteroids were
weaned while the ESR/CRP or muscle enzymes were ab-
normal. Methotrexate was given to 15 patients (0.6 mg/kg
to a maximum of 25 mg/day) and azathioprine to 2 as ster-
oid sparing agents. In a further 2 patients intravenous
cyclophosphamide was used, intravenous immunoglobulin
in 2 and rituximab in 1 patient. These agents were used to
treat severe relapsing muscle disease.
Diltiazem was tried in 8 patients for either the treat-
ment of or prevention of calcinosis. In 2 of these 5 chil-
dren with pre-existing calcinosis there was improvement
with resolution in some areas, but 2 of the 3 to whom it
was given prophylactically developed calcinosis. Chloro-
quine was prescribed in 4 patients for severe skin
disease.Follow-up and outcomes
At final review, 10 patients (47%) were in remission after an
average follow-up time of 3.2 years (range 1–8). This was
defined as being clinically asymptomatic and having normal
muscle enzymes and ESR and/or CRP. There were 4 pa-
tients with chronic disease with multiple relapses and ster-
oid dependence, of whom one subsequently improved
when given intravenous immunoglobulin. Two patients
had stopped treatment, relapsed, and were being re-treated.
A further 3 were lost to follow up and 2 died. The deaths
resulted from complications related to the disease (respira-
tory arrest due to severe muscle weakness in the first, 9
months after first onset of symptoms and interstitial lung
disease with pneumonia in the second, 3 months after first
onset of symptoms).
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African children and adults with JDM have been de-
scribed in the context of connective diseases; however,
we believe this is the first series of JDM in African chil-
dren. The typical features of JDM were proximal muscle
weakness and characteristic rashes, including vasculitic
ulcers, presenting either catastrophically or with slowly
progressive symptoms [13]. Other features particularly
present in our series included other musculoskeletal fea-
tures such as arthritis, pulmonary disease, and calcinosis.
Even if weakness is not a presenting complaint, in 95%
of cases it will be present on objective testing. In this
series of African children, 24% of children presented
with global rather than proximal weakness. These chil-
dren were younger at presentation with significantly
higher ESR and CRP values and were more likely to de-
velop contractures. This global weakness most likely rep-
resents severity in these young patients.
Calcinosis (dystrophic calcification) is a frequent and
distressing feature of JDM occurring in association with
increased local production of TNFα [9,10]. Calcinosis
occurs internationally in up to 40% of children [13], but
had a cumulative incidence of 71% in our series. Calci-
nosis is strongly associated with prolonged inflamma-
tion, as well as the vascular form of the disease [14], an
observation which holds true for this series of African
children in which skin vasculitis was significantly associ-
ated with calcinosis, especially in the presence of
Staphylococcus aureus. This subgroup of children, called
JDM with vasculopathy has been previously been de-
scribed to have a poorer prognosis overall in a study in
1983 by Bowyer et al. [14]. This study also identified the
time of onset of disease to initiation of therapy as of pri-
mary importance in the development of calcinosis, as
well as the use of low dose as opposed to high dose cor-
ticosteroids. This recommendation to use high dose ag-
gressive corticosteroid therapy and immunosuppressive
agents is commonly cited as central to control ongoing
inflammation thought to be of prime importance in the
development of dystrophic calcification in JDM [13].
However, the use of high dose corticosteroid in this
series of African children did not prevent the develop-
ment of calcinosis, nor were any differences apparent in
the time of onset of symptoms to initiation of therapy in
those with and without calcinosis. Interestingly, in a re-
cent series from India, despite the authors noting a delay
in presentation, only 18.2% developed calcinosis [15]. In
Scandinavia, only 20% developed calcinosis in associ-
ation with long term disease duration [16]. Our series is
in contrast to these reports as well as a study from Brazil
in which calcinosis was noted only in the more severe
cases, and cardiac involvement was identified being in-
dependently associated with calcinosis [17]. However, we
had only one child with cardiac disease in this series.Severity of disease in JDM is often associated with
high levels of muscle enzymes whereas a lack of calcino-
sis has been associated with lower CPK levels [18], even
though chronic disease is well described as the norm in
JDM [19]. The opposite has been true in this series,
where the calcinosis group as a whole has far lower
levels of CK, even in those who presented early. The
persistence of aldolase or LDH, although also lower than
the children in whom no calcinosis occurred, would
seem to be a better marker that there is ongoing inflam-
mation in these children.
Staphylococcal infections are common in children with
JDM, and have also been noted to play a role in dys-
trophic calcification. Moore et al. noted an association
between calcinosis and staphylococcal infections as each
child in their study that had calcinosis also developed
staphylociocal infections which they attributed to inter-
mittent defective granulocyte chemotaxis. They also
noted that these children had prolonged disease courses
and raised enzyme levels for prolonged periods of time
[20]. In our study, only 7 of the 15 children in the calci-
nosis group had staphylococcal infections, but they did
not have raised enzyme levels for prolonged periods.
The treatment of dystrophic calcification is generally
unsatisfactory, with prevention being the aim. While oral
corticosteroids as used in this series are the first line for
therapy of JDM, in the face of such high levels of calci-
nosis, IVMP may play a role, as well as the introduction
of methotrexate within six weeks of diagnosis [21,22].
Aggressive therapy is also being used internationally
now to induce early remission [23]. We have previously
introduced methotrexate from six weeks to three
months but this is now being used at diagnosis. Other
therapies that have been tried for calcinosis include dilti-
azem, aluminum hydroxide, probenicid and Bisphospho-
nates [24].
Conclusion
We have described a series of African children with
JDM. Whilst our series is small, and our conclusion may
be limited by numbers as well as all the problems inher-
ent in a cross sectional study, there have been several
differences which are at odds with the literature. Whilst
the heterogeneity of this disease extends across popula-
tions, differences in the disease course, response to ther-
apy and outcome may be due to genetic and local
environmental factors, and this may account for the ob-
served differences, particularly high incidence of calcino-
sis in our study group.
This group has high levels of vasculitic disease associated
with high levels of dystrophic calcification, in which the
there are lower levels of muscle enzymes, particular CK.
This is strongly suggestive of low grade chronic inflamma-
tion in this group, and aggressive immunosuppressant use
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trexate and the use of cyclophosphamide and intravenous
immunoglobulin is now employed. This regimen is also
used for the younger children, whom we have shown in this
series to be at higher risk of contractures and thus long
term disability. Muscle enzymes are also an unreliable
marker of disease, and clinical measurement of muscle
strength is now used rather than laboratory evidence to
measure response to therapy. Our patients, particularly in
the face of high levels of calcinosis, are at high risk of the
developing Staphylococcus Aureus infection, an observa-
tion which has lead our unit to institute the practice of rou-
tine cloxacillin prophylaxis. There would thus appear to be
a role overall for more rapid and aggressive therapy even in
the face of what appears to be mild disease in African
children.
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